Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$25.07 +1.1%	$25.38	$22.64 ▼ $53.96	$1.19B	0.78	478,478 shs	482,087 shs
BGM Qilian International Holding Group	$12.36 +0.1%	$10.97	$5.26 ▼ $14.78	$1.20B	1.33	26,468 shs	9,300 shs
CGC Canopy Growth	$1.77 +7.9%	$1.19	$0.77 ▼ $10.71	$325.44M	0.79	5.72 million shs	9.42 million shs
OCUL Ocular Therapeutix	$7.60 +1.2%	$7.38	$4.79 ▼ $11.78	$1.21B	1.51	1.40 million shs	1.20 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	+1.13%	+4.98%	+7.37%	-19.67%	-41.79%
BGM Qilian International Holding Group	+1.48%	+8.61%	+10.74%	+21.35%	+1,235,999,900.00%
CGC Canopy Growth	+7.93%	+22.07%	+48.74%	+5.99%	-82.53%
OCUL Ocular Therapeutix	+1.20%	+8.57%	+3.97%	+2.98%	+20.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.2856 of 5 stars	3.1	1.0	0.0	3.7	3.3	4.2	1.3
BGM Qilian International Holding Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	1.4385 of 5 stars	1.5	2.0	0.0	0.0	2.2	0.0	1.3
OCUL Ocular Therapeutix	4.2953 of 5 stars	3.4	3.0	0.0	4.1	4.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	28.97% Upside
BGM Qilian International Holding Group	0.00	N/A	N/A	N/A
CGC Canopy Growth	1.00	Sell	$2.00	12.99% Upside
OCUL Ocular Therapeutix	2.88	Moderate Buy	$16.25	113.82% Upside

Current Analyst Ratings Breakdown

Latest CGC, BGM, OCUL, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00
5/8/2025	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $35.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/10/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/8/2025	OCUL Ocular Therapeutix	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/21/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $32.00
3/18/2025	OCUL Ocular Therapeutix	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
3/11/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
3/4/2025	OCUL Ocular Therapeutix	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$19.00
3/4/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$730.66M	1.63	$3.50 per share	7.17	$13.35 per share	1.88
BGM Qilian International Holding Group	$25.10M	47.88	N/A	N/A	$6.10 per share	2.03
CGC Canopy Growth	$276.75M	1.18	N/A	N/A	$2.72 per share	0.65
OCUL Ocular Therapeutix	$59.65M	20.30	N/A	N/A	$0.79 per share	9.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$137.54M	$2.76	8.36	7.62	2.19	21.80%	26.44%	11.89%	8/6/2025 (Estimated)
BGM Qilian International Holding Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	-$487.23M	-$3.80	N/A	N/A	N/A	-156.98%	-56.52%	-24.18%	5/30/2025 (Confirmed)
OCUL Ocular Therapeutix	-$80.74M	-$1.15	N/A	N/A	N/A	-283.74%	-45.18%	-30.87%	8/6/2025 (Estimated)

Latest CGC, BGM, OCUL, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/30/2025	Q4 2025	CGC Canopy Growth	-$0.28	N/A	N/A	N/A	$71.84 million	N/A
3/3/2025	Q4 2024	OCUL Ocular Therapeutix	-$0.24	-$0.29	-$0.05	-$0.29	$16.89 million	$17.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BGM Qilian International Holding Group	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.82	3.43	2.61
BGM Qilian International Holding Group	N/A	3.39	2.82
CGC Canopy Growth	0.74	3.52	2.58
OCUL Ocular Therapeutix	0.19	13.01	12.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
BGM Qilian International Holding Group	N/A
CGC Canopy Growth	3.33%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.50%
BGM Qilian International Holding Group	58.66%
CGC Canopy Growth	1.30%
OCUL Ocular Therapeutix	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,620	47.50 million	35.05 million	Optionable
BGM Qilian International Holding Group	298	97.22 million	2.48 million	N/A
CGC Canopy Growth	3,150	183.87 million	153.39 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	151.71 million	Optionable

CGC, BGM, OCUL, and AMPH Headlines

Recent News About These Companies

Graham Capital Management L.P. Takes $321,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 20 at 4:21 AM | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Second Line Capital LLC

May 19 at 6:45 AM | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Point72 Asset Management L.P.

May 19 at 5:53 AM | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Boosted by Northern Trust Corp

May 19 at 3:17 AM | marketbeat.com

Polar Asset Management Partners Inc. Trims Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 18 at 6:08 AM | marketbeat.com

Balyasny Asset Management L.P. Acquires New Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 17, 2025 | marketbeat.com

Patient Square Capital LP Raises Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 16, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Boosted by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

May 15, 2025 | marketbeat.com

Richard L. Md Lindstrom Purchases 10,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

May 14, 2025 | marketbeat.com

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

May 14, 2025 | globenewswire.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Director Richard L. Md Lindstrom Acquires 10,000 Shares

May 13, 2025 | insidertrades.com

HC Wainwright Expects Weaker Earnings for Ocular Therapeutix

May 10, 2025 | marketbeat.com

William Blair Cuts Earnings Estimates for Ocular Therapeutix

May 10, 2025 | marketbeat.com

What is HC Wainwright's Forecast for OCUL FY2026 Earnings?

May 9, 2025 | marketbeat.com

Deep Track Capital LP Grows Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 9, 2025 | marketbeat.com

Analyst Expectations For Ocular Therapeutix's Future

May 8, 2025 | nasdaq.com

Ocular Therapeutix (NASDAQ:OCUL) Trading Down 6.5% on Analyst Downgrade

May 8, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Price Target Cut to $14.00 by Analysts at Needham & Company LLC

May 8, 2025 | marketbeat.com

212,944 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Acquired by First Trust Advisors LP

May 8, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down - What's Next?

May 7, 2025 | marketbeat.com

VIDEO: OTX-TKI reduces intraretinal fluid over 1 year with single injection

May 7, 2025 | healio.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGC, BGM, OCUL, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$25.07 +0.28 (+1.13%)

As of 05/20/2025 04:00 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Qilian International Holding Group NASDAQ:BGM

$12.36 +0.01 (+0.08%)

As of 05/20/2025 02:09 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Canopy Growth NASDAQ:CGC

$1.77 +0.13 (+7.93%)

As of 05/20/2025 04:00 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Ocular Therapeutix NASDAQ:OCUL

$7.60 +0.09 (+1.20%)

As of 05/20/2025 04:00 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time